---
schema_version: "secwatch.filing_event.v1"
accession: "0000059478-22-000277"
form_type: "8-K"
ticker: "LLY"
cik: "0000059478"
company_name: "ELI LILLY & Co"
filed_at: "2022-12-13T23:59:59+00:00"
generated_at: "2026-06-21T05:48:04.121677+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Lilly guides 2023 revenue $30.3B-$30.8B, EPS $7.65-$7.85; plans four new drug launches

## Summary
- 2023 revenue guidance $30.3B-$30.8B, up from 2022 reaffirmed $28.5B-$29.0B.
- 2023 reported EPS $7.65-$7.85; non-GAAP EPS $8.10-$8.30; 2022 reaffirmed $6.50-$6.65 reported.
- Plans to launch donanemab, mirikizumab, lebrikizumab, pirtobrutinib; potential tirzepatide obesity submission.
- Fifth consecutive 15% annual dividend increase; R&D spend $8.2B-$8.4B vs $7.1B-$7.3B 2022.
- Gross margin ~77% reported, ~79% non-GAAP; tax rate ~16%; Alimta LOE and FX headwinds.

## SEC filing metadata
- accession: 0000059478-22-000277
- form_type: 8-K
- ticker: LLY
- cik: 0000059478
- company_name: ELI LILLY & Co
- filed_at: 2022-12-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/59478/000005947822000277/0000059478-22-000277-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/59478/000005947822000277/lly-20221213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000059478-22-000277
- JSON: https://secwatch.observer/filing/0000059478-22-000277.json
- Plain text: https://secwatch.observer/filing/0000059478-22-000277.txt

## Key facts
- Earnings Releases
  ELI LILLY & Co reported FY2023 results: revenue $30.3 billion to $30.8 billion, EPS $7.65 to $7.85 on a reported basis and $8.10 to $8.30 on a non-GAAP basis.
  - Period: FY2023
  - Revenue: $30.3 billion to $30.8 billion
  - EPS: $7.65 to $7.85 on a reported basis and $8.10 to $8.30 on a non-GAAP basis
  - Result: guidance update
  source text: 2023 revenue expected to be between $30.3 billion and $30.8 billion, driven by key growth products. • 2023 EPS expected to be in the range of $7.65 to $7.85 on a reported basis and $8.10 to $8.30 on a non-GAAP basis.
  evidence_url: https://www.sec.gov/Archives/edgar/data/59478/000005947822000277/0000059478-22-000277-index.htm
- Earnings Releases
  ELI LILLY & Co reported FY2022 results: revenue $28.5 to $29.0 billion, EPS $6.50 to $6.65 on a reported basis and $7.70 to $7.85 on a non-GAAP basis. Guidance reaffirmed.
  - Period: FY2022
  - Revenue: $28.5 to $29.0 billion
  - EPS: $6.50 to $6.65 on a reported basis and $7.70 to $7.85 on a non-GAAP basis
  - Guidance: reaffirmed
  - Result: guidance update
  source text: IPR&D or development milestone charges incurred during Q4 2022. 2 The company reaffirmed its 2022 financial guidance, as set forth in the following table: 2022 Guidance Revenue $28.5 to $29.0 billion Gross Margin % of Revenue (reported) Approx. 76% Gross Margin % of Revenue (non-GAAP) Approx. 78% Marketing, Selling & Administrative $6.4 to $6.6 billion
  evidence_url: https://www.sec.gov/Archives/edgar/data/59478/000005947822000277/0000059478-22-000277-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.